A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
Trial Details
- NCT ID
- NCT07133425
- Phase
- PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Non-Small Cell (NSCLC) Lung Cancer
- Interventions
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Eligibility Criteria
- Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures.
- Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, children …
- Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all availabl…
For full eligibility, visit ClinicalTrials.gov.